EUVIMEDEUVIMED entdecken
Crossref

Initiation of molecular testing of endometrial carcinomas in a population‐based setting: practical considerations and pitfalls

Jesús Machuca-Aguado, Mark Catherwood, Oisin Houghton, Jennifer Taylor, Rajeev Shah, Ali Ben-Mussa, David Gonzalez, W Glenn McCluggage iD

Histopathology · 2025

DOI: 10.1111/his.15365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Jesús Machuca-Aguado und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Virgen Macarena University Hospital, Seville, Spain. Hauptthemen laut MEDLINE: Carcinoma, DNA Mismatch Repair, DNA Polymerase II, Endometrial Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Since the publication of The Cancer Genome Atlas (TCGA) molecular Classification of endometrial carcinomas in 2013, multiple studies have demonstrated the prognostic and therapeutic importance of this. However, there is great variability on whether and how this is undertaken in different institutions, and this is often dependent on resources and availability of molecular testing. Points of controversy include whether molecular classification is needed on all endometrial carcinomas and whether pure molecular testing is undertaken or a surrogate such as the ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) Classifier. Herein we report our experience instigating molecular classification of endometrial carcinomas in Northern Ireland. Methods and Results From 1st March 2023, all endometrial carcinomas diagnosed on biopsy in the four pathology laboratories in Northern Ireland were referred to the central molecular pathology laboratory for genomic analysis using a custom next‐generation sequencing (NGS) panel; the NGS panel included the entire coding regions of polymerase epsilon ( POLE ) and TP53 genes, as well as microsatellite instability (MSI) analysis. All cases also underwent immunohistochemical staining with oestrogen receptor (ER), p53, and the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. The molecular results were available by the time of surgery (if a hysterectomy was performed) allowing integration into the final pathology report where a TCGA molecular type was assigned. Two hundred and sixty‐seven endometrial carcinomas underwent molecular testing; in five cases, there was insufficient material for testing, leaving 262 cases. The TCGA groups were POLE mut (19; 7.3%), MMRd (63; 24%), p53abn (62; 23.7%), and no specific molecular profile (NSMP) 118 (45%). Seventeen tumours (6.5%) were “multiple‐classifiers”: five POLE mut‐p53abn, two POLE mut‐MMRd, one POLE ‐MMRd‐p53abn (all included in the POLE mut TCGA group), and nine MMRd‐p53abn (included in the MMRd group).

Conclusion

This represents one of the first population‐based studies investigating the prevalence of the different TCGA molecular groups of endometrial carcinomas in an unselected population. Performing molecular testing on biopsies enables management to be tailored to the molecular group and allows integration of the TCGA group into the report of the final resection specimen. We hope our experience will facilitate other laboratories in undertaking TCGA molecular classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinomaDNA Mismatch RepairDNA Polymerase IIEndometrial NeoplasmsTumor Suppressor Protein p53AdultAgedFemaleHumansMiddle AgedHigh-Throughput Nucleotide SequencingIrelandMolecular Diagnostic TechniquesMicrosatellite InstabilityAged, 80 and overBiomarkers, Tumor

Stichwörter der Autor:innen

POLETCGAendometrial carcinomaimmunohistochemistrymolecular testingp53

Substanzen

DNA Polymerase IITP53 protein, humanTumor Suppressor Protein p53Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Virgen Macarena University Hospital, Seville, Spain.
  • Regional Molecular Diagnostics Service, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
  • Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
  • Department of Pathology, Southern Health and Social Care Trust, Craigavon, Northern Ireland, UK.
  • Department of Pathology, Western Health and Social Care Trust, Londonderry, Northern Ireland, UK.
  • Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.

ORCID-Profile: W Glenn McCluggage

Zitieren

APA

Machuca-Aguado, J., Catherwood, M., Houghton, O., Taylor, J., Shah, R., Ben-Mussa, A., Gonzalez, D., & McCluggage, W. G. (2025). Initiation of molecular testing of endometrial carcinomas in a population‐based setting: practical considerations and pitfalls. Histopathology. https://doi.org/10.1111/his.15365

Vancouver

Machuca-Aguado J, Catherwood M, Houghton O, Taylor J, Shah R, Ben-Mussa A, et al. Initiation of molecular testing of endometrial carcinomas in a population‐based setting: practical considerations and pitfalls. Histopathology. 2025. doi:10.1111/his.15365

BibTeX
@article{MachucaAguado2025,
  author = {Machuca-Aguado, Jesús and Catherwood, Mark and Houghton, Oisin and Taylor, Jennifer and Shah, Rajeev and Ben-Mussa, Ali and Gonzalez, David and McCluggage, W Glenn},
  title = {Initiation of molecular testing of endometrial carcinomas in a population‐based setting: practical considerations and pitfalls},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15365}
}
Kostenlos starten →